# EDGAR Filing Document

**Accession Number:** 0001135041
**File Stem:** 0001493152-26-026426
**Filing Date:** 2026-5
**Character Count:** 10450
**Document Hash:** d8890f50d06ce24cb7532075e47eefa9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-026426.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001493152-26-026426

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260522

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CHANG NANCY T
- **CENTRAL INDEX KEY:** 0001135041

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41159
- **FILM NUMBER:** 261045856

**MAIL ADDRESS:**
- **STREET 1:** 101 WESTCOTT
- **STREET 2:** SUITE 603
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immix Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001873835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 454869378
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11400 WEST OLYMPIC BLVD.
- **STREET 2:** SUITE 200
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** (888) 958-1084

**MAIL ADDRESS:**
- **STREET 1:** 10573 W. PICO BLVD.
- **STREET 2:** #58
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

## Exhibit 24.1

**Exhibit 24.1**

LIMITED POWER OF ATTORNEY FOR

SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Ilya Rachman and Gabriel Morris of Immix Biopharma, Inc. (the "Company"), signing singly, the undersigned's true and lawful attorney-in-fact and agent to:

&nbsp;&nbsp;&nbsp;&nbsp;(1) prepare,
 execute on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission
 (the "SEC") any documents necessary or advisable to obtain EDGAR access codes
 or make any updates to the undersigned's EDGAR access codes once obtained, enabling
 the undersigned to make electronic filings of reports with the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;(2) execute
 for and on behalf of the undersigned, an officer, director or holder of 10% of more of a
 registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section
 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")
 and the rules thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;(3) do
 and perform any and all acts for and on behalf of the undersigned that may be necessary or
 desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment
 or amendments thereto, and timely file such forms or amendments with the SEC and any stock
 exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;(4) take
 any other action of any nature whatsoever in connection with the foregoing which, in the
 opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally
 required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
 on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and
 shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's
 discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact or (c) until both of such attorneys-in-fact shall no longer be employed by the Company, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 26, 2026.

---

| |
|:---|
| /s/ Nancy T. Chang |
| Nancy T. Chang |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CHANG NANCY T<br><sub>(Last) (First) (Middle)</sub><br>C/O IMMIX BIOPHARMA, INC.<br>11400 WEST OLYMPIC BLVD., SUITE 200<br><sub>(Street)</sub><br>LOS ANGELES, CA 90064<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Immix Biopharma, Inc. [ IMMX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-22 |  | A |  | 6250<sup>(1)</sup> | A | $0 | 428190 | D |  |
| Common Stock |  |  |  |  |  |  |  | 496940 | I | Held by Robinhood II, LP<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $8.78 | 2026-05-22 |  | A |  | 12500 |  | <sup>(3)</sup> | 2036-05-22 | Common Stock | 12500 | $0 | 12500 | D |  |

---

### Footnotes:

(1) The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

(2) The Reporting Person is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.

(3) The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

**Remarks:**
Exhibit 24.1 - Powers of Attorney

**Signature:** /s/ Ilya Rachman as Attorney-In-Fact for Nancy T. Chang  
**Date:** 2026-05-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**